‌

US Patent 11890276 Methods of treating pancreatic cancer

Patent 11890276 was granted and assigned to ChemoCentryx on February, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Shichang Miao0

Petrus Bekker0

Tom Schall0

Israel Charo0

Date of Patent

February 6, 2024

0

Patent Application Number

174456400

Date Filed

August 23, 2021

0

Patent Citations

US Patent 8754107 Aminopyrrolidines as chemokine receptor antagonists

0

US Patent 9394307 Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation

0

US Patent 9745312 Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation

0

US Patent 10583131 Methods of treating pancreatic cancer

0

US Patent 10195188 Method of treating pancreatic cancer

0

US Patent 7622583 Heteroaryl sulfonamides and CCR2

0

US Patent 7884110 Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation

0

US Patent 8093247 Heteroaryl sulfonamides and CCR2

0

...

Patent Primary Examiner

0

CPC Code

0

0

0

0

0

0

0

0

...

Patent abstract

The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11890276 Methods of treating pancreatic cancer

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.